Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease.

Nature aging·2026
Same author

The myth of digital biomarkers in Alzheimer's disease: how to make them a reality.

Current opinion in psychiatry·2026
Same author

A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia.

Nature medicine·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Farhad Imam1

  • 1Gates Ventures, Seattle, WA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary

The Global Neurodegeneration Proteomics Consortium (GNPC) created a large dataset of over 300 million protein measures from 40,000 analyses. This resource aims to advance understanding and develop biomarkers for neurodegenerative diseases like Alzheimer's and Parkinson's.

Area of Science:

  • Neuroscience
  • Proteomics
  • Biomarker Discovery

Background:

  • Understanding neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, FTD) is limited, hindering biomarker and treatment development.
  • Large, harmonized patient-derived datasets are crucial for unraveling complex neurodegenerative biology.
  • The Global Neurodegeneration Proteomics Consortium (GNPC) established a major proteomic dataset with ~300 million measures from ~40,000 biosamples.

Purpose of the Study:

  • To create a large, harmonized proteomic dataset for neurodegenerative disease research.
  • To overcome legal, technological, and incentive barriers to data sharing.
  • To provide a global resource for researchers to analyze proteomic and clinical data.

Main Methods:

  • Harmonized 23 heterogeneous clinical and proteomic datasets.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702
  • Addressed barriers to open data sharing.
  • Hosted the harmonized dataset on the Alzheimer's Disease Data Initiative's AD Workbench.

    • Main Results:

    • The Harmonized Dataset (HDS) version 1 contains ~40,000 proteomic analyses (SomaScan, Olink, mass spectrometry).
    • All samples include 50 phenotypic indicators (demographics, cognitive, clinical, genotype).
    • Data is securely hosted on AD Workbench with compute resources for >100 researchers.

    Conclusions:

    • The GNPC dataset is one of the largest protein biomarker discovery efforts for neurodegenerative diseases.
    • Preliminary analyses will identify diagnostic and predictive proteomic biomarker signatures.
    • Findings will advance understanding of pan-neurodegeneration and disease-specific states.